Screening for inhibitors of tau polymerization

Current Alzheimer Research

Volumn 2, Issue 2, 2005, Pages 219-226

  Pickhardt, Marcus ^a   Von Bergen, Martin ^a   Gazova, Zuzana ^a   Hascher, Antje ^a   Biernat, Jacek ^a   Mandelkow, Eva Maria ^a   Mandelkow, Eckhard ^a  

^a MAX PLANCK UNIT FOR STRUCTURAL MOLECULAR BIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; DIRECT YELLOW 7; PROTEIN INHIBITOR; TAU PROTEIN; THIOFLAVINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ASSAY; CELL VIABILITY; CONFERENCE PAPER; DEPOLYMERIZATION; ELECTRON MICROSCOPY; FILTER TRAPPING; FLUORESCENCE; HISTOPATHOLOGY; NERVE CELL; PAIRED HELICAL FILAMENT; PELLETING; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN POLYMERIZATION;

ALZHEIMER DISEASE; DRUG EVALUATION, PRECLINICAL; HUMANS; MICROTUBULES; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; TAU PROTEINS;

EID: 20844432208     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/1567205053585891     Document Type: Conference Paper

References (61)

1. Selkoe DJ, Schenk D. Alzlieimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43:545-84(2003).
2. Higuchi M, Lee VM, Trojanowski JQ. Tau and axonopathy in neurodegenerative disorders. Neuromolecular Med 2(2):131-50 (2002).
3. Buee L, Hamdane M, Delobel P, Sambo AV, Begard S, Ghestem A, Sergeant N, Delacourte A. [Tau story: from frontotemporal dementia to other tauopathies]. J Soc Biol 196(1):103-8 (2002).
4. Caughey B, Lansbury PT, Jr. Protofibrils, Pores, Fibrils, and Neurodegeneration: Separating the Responsible Protein Aggregates from the Innocent Bystanders. Annu Rev Neurosci (2003).
5. Petersen A, Hansson O, Brundin P. [Huntington disease - yet another mad protein?]. Lakartidningen 98(50):5756-8, 5761 (2001).
6. Trojanowski JQ, Lee VM. Parkinson's disease and related alpha-synucleinopathies are brain amyloidoses. Ann N Y Acad Sci 991:107-10 (2003).
7. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82(4):239-59 (1991).
8. Ball MJ, Murdoch GH. Neuropathological criteria for the diagnosis of Alzlieimer's disease: are we really ready yet? Neurobiol Aging 18(4 Suppl):S3-12 (1997).
9. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83(13):4913-7 (1986).
10. Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E. Phosphorylation of serine 262 strongly reduces the binding of tau protein to microtubules: Distinction between PHF-like immunoreactivity and microtubule binding. Neuron 11:153-163. (1993).
11. Friedhoff P, von Bergen M, Mandelkow EM, Davies P, Mandelkow E. A nucleated assembly mechanism of Alzheimer paired helical filaments. Proc Natl Acad Sci USA 95(26):15712-7 (1998).
12. King ME, Ahuja V, Binder LI, Kuret J. Ligand-dependent tau filament formation: implications for Alzheimer's disease progression. Biochemistry 38(45):14851-9 (1999).
13. Wilson DM, Binder LI. Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. Am J Pathol 150(6):2181-95 (1997).
14. Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow EM. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38(12):3549-58 (1999).
15. Iqbal K, Grundke-Iqbal I, Smith AJ, George L, Tung YC, Zaidi T. Identification and localization of a tau peptide to paired helical filaments of Alzheimer disease. Proc Natl Acad Sci USA 86(14):5646-50 (1989).
16. Wischik CM, Novak M, Edwards PC, Klug A, Tichelaar W, Crowther RA. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci USA 85(13):4884-8 (1988).
17. Ledesma MD, Bonay P, Colaco C, Avila J. Analysis of microtubule- associated protein tau glycation in paired helical filaments. J Biol Chem 269(34):21614-9 (1994).
18. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci USA 100(17):10032-7 (2003).
19. Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, LaFerla FM, Rohn TT, Cotman CW. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 114(1):121-30 (2004).
20. Novak M, Kabat J, Wischik CM. Molecular characterization of the minimal protease resistant tau-unit of the Alzheimer's-disease paired helical filament. EMBO J. 12:365-370. (1993).
21. Wille H, Drewes G, Biernat J, Mandelkow EM, Mandelkow E. Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J Cell Biol 118(3):573-84 (1992).
22. Friedhoff P, Schneider A, Mandelkow EM, Mandelkow E. Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution. Biochemistry 37(28):10223-30 (1998).
23. Volles MJ, Lansbury PT, Jr. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42(26):7871-8 (2003).
24. Goedert M, Spillantini MG, Davies SW. Filamentous nerve cell inclusions in neurodegenerative diseases. Curr Opin Neurobiol 8(5):619-32 (1998).
25. Bates G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 361(9369):1642-4 (2003).
26. Sanchez I, Mahlke C, Yuan J. Pivolal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421(6921):373-9 (2003).
27. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400(6740):173-7 (1999).
28. Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE, Klein WL. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem 79(3):595-605 (2001).
29. Beirao I, Lobato L, Riedstra S, Costa PM, Pimentel S, Guimaraes S. Ineffectiveness of dialysis in transthyretin (TTR) clearance in familial amyloid polyneuropathy type 1, in spite of lower stability of the TTR Met30 variant. Clin Nephrol 51(1):45-9 (1999).
30. Schweers O, Mandelkow EM, Biernat J, Mandelkow E. Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. Proc Natl Acad Sci USA 92(18):8463-7 (1995).
31. Schweers O, Schonbrunn-Hanebeck E, Marx A, Mandelkow E. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. J Biol Chem 269(39):24290-7 (1994).
32. von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQ1VYK (311)) forming beta structure. Proc Natl Acad Sci USA 97(10):5129-34 (2000).
33. Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 11(1):153-63 (1993).
34. Li L, von Bergen M, Mandelkow EM, Mandelkow E. Structure, stability, and aggregation of paired helical filaments from tau protein and FTDP-17 mutants probed by tryptophan scanning mutagenesis. J Biol Chem 277(44):41390-400 (2002).
35. Scherzinger E, Sittler A, Schweiger K, Heiser V, Lurz R, Hasenbank R, Bates GP, Lehrach H, Wanker EE. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc Natl Acad Sci USA 96(8):4604-9. (1999).
36. Barghorn S, Mandelkow E. Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments. Biochemistry 41(50):14885-96 (2002).
37. Benditt EP, Eriksen N, Berglund C. Congo red dichroism with dispersed amyloid fibrils, an extrinsic cotton effect. Proc Natl Acad Sci USA 66(4):1044-51 (1970).
38. Hoyer W, Antony T, Cherny D, Heim G, Jovin TM, Subramaniam V. Dependence of alpha-synuclein aggregate morphology on solution conditions. J Mol Biol 322(2):383-93 (2002).
39. Chili F, Webster P, Taddei N, Clark A, Stefani M, Ramponi G, Dobson CM. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci USA 96(7):3590-4. (1999).
40. De Felice FG, Vieira MN, Meirelles MN, Morozova-Roche LA, Dobson CM, Ferreira ST. Formation of amyloid aggregates from human lysozyme and its disease-associated variants using hydrostatic pressure. Faseb J 18(10): 1099-101 (2004).
41. Nilsson MR, Dobson CM. In vitro characterization of lactoferrin aggregation and amyloid formation. Biochemistry 42(2):375-82 (2003).
42. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 3(9):519-27 (2004).
43. Westermark GT, Johnson KH, Westermark P. Staining methods for identification of amyloid in tissue. Methods Enzymol 309:3-25 (1999).
44. Kimura Y, Koitabashi S, Fujita T. Analysis of yeast prion aggregates with amyloid-staining compound in vivo. Cell Struct Fund 28(3):187-93 (2003).
45. Boshuizen RS, Langeveld JP, Salmona M, Williams A, Meloen RH, Langedijk JP. An in vitro screening assay based on synthetic prion protein peptides for identification of fibril-interfering compounds. Anal Biochem 333(2):372-80 (2004).
46. Chirita CN, Necula M, Kuret J. Anionic micelles and vesicles induce tau fibrillization in vitro. J Biol Chem 278(28):25644-50 (2003).
47. Iqbal K, Zaidi T, Thompson CH, Merz PA, Wisniewski HM. Alzheimer paired helical filaments: bulk isolation, solubility, and protein composition. Acta Neuropathol 62(3):167-77 (1984).
48. Pickhardt M, Gazova Z, von Bergen M, Khlistunova I, Wang Y, Hascher A, Mandelkow EM, Biernat J, Mandelkow E. Anthraquinones inhibit tau aggregation and dissolve alzheimer paired helical filaments in vitro and in cells. J Biol Chem (2004).
49. Gamblin TC, King ME, Dawson H, Vitek MP, Kuret J, Berry RW, Binder LI. In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants. Biochemistry 39(20):6136-44 (2000).
50. Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CC. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol 273(3):729-39 (1997).
51. von Bergen M, Barghorn S, Li L, Marx A, Biernat J, Mandelkow EM, Mandelkow E. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J Biol Chem 276(51):48165-74 (2001).
52. Gazit E. A possible role for pi-stacking in the self-assembly of amyloid fibrils. FASEB J 16(1):77-83 (2002).
53. Selkoe DJ. Folding proteins in fatal ways. Nature 426(6968):900-4 (2003).
54. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, Feany MB. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293(5530):711-4 (2001).
55. Nishimura I, Yang Y, Lu B. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 116(5):671-82 (2004).
56. Cruz JC, Tsai LH. Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol Med 10(9):452-8 (2004).
57. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33(1):95-130 (2000).
58. Ingram EM, Spillantini MG. Tau gene mutations: dissecting the pathogenesis of FTDP-17. Trends Mol Med 8(12):555-62 (2002).
59. Horowitz PM, Patterson KR, Guillozet-Bongaarts AL, Reynolds MR, Carroll CA, Weintraub ST, Bennett DA, Cryns VL, Berry RW, Binder LI. Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease. J Neurosci 24(36):7895-902 (2004).
60. Shimura H, Schwartz D, Gygi SP, Kosik KS. CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem 279(6):4869-76 (2004).
61. Shimura H, Miura-Shimura Y, Kosik KS. Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J Biol Chem 279(17):17957-62 (2004).